Additive effect of tDCS and neuromotor recruitment on functional recovery in chronic paraplegia: A randomized controlled trial Authors: Ahmad Rifai Sarraj, Jihan Allaw, Eliane Rached, Joy Khayat, Hassan Karaki, Ahmad Diab, Antonio Pinti, Mohammad Sidiq, Mohammad Sidiq, Mohammad Sidiq, Mohammad Sidiq, Mohammad Sidiq Published: 2026 ABSTRACT Functional recovery in chronic spinal cord injury (SCI) is traditionally viewed as limited, particularly after the spontaneous recovery window has closed. This single-blind randomized controlled trial investigated whether adding anodal Transcranial Direct Current Stimulation (tDCS) to the Neuromotor Recruitment Method (NEUROM)—a protocol combining motor imagery with intensive peripheral sensory stimulation—provides a additive benefit for sensorimotor recovery. Fifty participants with chronic paraplegia (mean time since injury: 15.4 ± 3.2 months; ASIA Impairment Scale A, B, or C) were recruited and randomized into three arms: Reference (standard care, n = 10), NEUROM (n = 20), or NEUROM+tDCS (n = 20). The intervention was administered over 10 days. Outcomes included the Lower Extremity Motor Score (LEMS), Light Touch and Pin Prick sensory scores, and the Assessment of Movement Attempt (AMA). The Reference group showed no significant recovery. Both active groups (NEUROM and NEUROM+tDCS) achieved substantial and statistically identical improvements in sensory function compared to the Reference group (p < 0.001), suggesting that peripheral recruitment alone is sufficient for afferent restoration. However, a significant dissociation was observed in motor function: the NEUROM+tDCS group demonstrated superior LEMS recovery (Mean change: 18 points) compared to the NEUROM group (14 points; p = 0.01) and reported significantly higher volitional drive (p < 0.001). These findings indicate a clear dissociation between sensory and motor plasticity in chronic SCI; while peripheral somatosensory recruitment drives afferent sensory restoration, the addition of central stimulation via tDCS is critical for maximizing efferent motor output. This suggests that restoring motor function in chronic paraplegia requires a “top-down” cortical prime to complement “bottom-up” peripheral signaling. Trial Registration: ClinicalTrials.gov NCT04790149. Introduction Spinal cord injury (SCI) is a debilitating condition that results in the loss of motor and sensory functions. Historically, the spinal cord has been described as a protected bundle of nerves connecting the brain to the body, mediating motor, sensory, and some autonomic functions below the neck (for a historical review, see [1], also [2]). Traumatic Spinal Cord Injury (TSCI) is a catastrophic and unexpected event that can occur along the spinal column (cervical, thoracic, and lumbar). The global incidence rate (2007) is estimated at 23 TSCI cases per million, totaling approximately 179,312 cases annually [3]. TSCI often results in life-threatening conditions, including varying degrees of motor paralysis, sensory loss, and impairment of bowel, bladder, sexual, and other physiological functions. Recent studies highlight that TSCI can lead to severe and potentially life-threatening syndromes such as autonomic dysreflexia [4]. Reorganization of the central nervous system (CNS) after injury has been demonstrated in both animals and humans, improving our understanding of the repair processes that can occur through various mechanisms [5]. Spontaneous functional recovery after SCI may depend on substantial reorganization of propriospinal circuits and the amount of spared axons that can contribute to functional gains over time [6]. Additionally, surviving fibers may produce adaptive rewiring of spared interneurons, significantly impacting post-SCI plasticity and enabling patients to regain their previous motor and functional abilities [6]. Operant conditioning protocols in animals and humans, including activation of the corticospinal tract, can produce multiple structural changes and plasticity in the spinal cord. These changes include modifications in motor neuron firing thresholds, axonal conduction velocity, and synaptic terminals on motor neurons. This activity-dependent plasticity, driven by input from the periphery and/or the brain, plays a crucial role in the acquisition and maintenance of motor skills after SCI [7]. Neurorehabilitation has been demonstrated to be effective in inducing and guiding histological and/or functional recovery in SCI patients [8]. Clinical trials recommend replacing conventional and compensatory rehabilitative strategies, which often involve braces, assistive devices, and wheelchairs, with restorative strategies. These restorative therapies aim to achieve activation of the neurologically injured level through function-specific motor tasks and intensive exercise training, optimizing functional, metabolic, and neurological status in SCI patients [9–12]. Functional magnetic resonance imaging (fMRI) studies have found strong associations between motor task-related fMRI activation and the degree of motor function post-SCI. For instance, increased fMRI activation within sensorimotor and premotor networks has been correlated with improved locomotor function and motor skill acquisition after SCI [13]. Similarly, the extent of activation in the primary motor cortex (M1) is often linked to the degree of motor recovery, suggesting that motor imagery, action observation, and other cognitive stimuli combined with functional and restorative exercises can effectively engage larger cortical networks, leading to better recovery outcomes [14]. Following SCI, the spinal cord is deprived of descending inputs from the brain. However, sensory inputs may still persist, and peripheral sensory inputs can target adaptive changes in spared axons within below-level neuronal networks of the spinal cord. For example, muscle stretching can generate specific peripheral sensory input in muscle receptors, potentially provoking central sensitization and facilitating adaptive plasticity [15]. These findings highlight the importance of integrating motor imagery and peripheral sensory inputs into rehabilitation protocols to promote neuroplasticity and functional recovery in SCI patients. The combination of these techniques can enhance the activation of cortical and spinal networks, leading to significant improvements in motor and sensory functions. In this study, we propose an experimental rehabilitative protocol for TSCI patients based on the histological and/or functional reorganization model of the spinal cord after injury, as well as activity-dependent plasticity and motor imagery. This method may enhance sparing-induced plasticity and facilitate learned-reflex modulation within interneuron networks. Furthermore, non-invasive brain stimulation, specifically Transcranial Direct Current Stimulation (tDCS), has been shown to modulate cortical excitability and prime the motor cortex for learning [16,17]. We hypothesized that “priming” the cortex with tDCS prior to the NEUROM protocol would create an additive effect, enhancing functional recovery more than either modality alone. Materials and methods Study design and participants This study utilized a randomized, controlled, single-blind experimental design conducted over a period of 3 weeks. The study protocol was registered at ClinicalTrials.gov (Identifier: NCT04790149). We acknowledge that the administrative registration of this trial was completed after the initial ethical approval was granted. This delay was directly caused by the onset of the COVID-19 pandemic, which necessitated a strict, institutional freeze on patient recruitment across our multicenter clinical sites for the safety of this vulnerable population. Consequently, the practical start of the study and the initiation of active patient enrollment were delayed until December 1, 2022. We confirm that despite this administrative disruption, the study protocol remained strictly aligned with the original ethical approval. Absolutely no modifications or changes were made to the study design, interventions, or procedures after registration. The authors confirm that all ongoing and related trials for this drug/intervention are registered. As a multicenter study, the protocol underwent rigorous prospective review and was approved by the respective Institutional Review Boards, including the Ethics Committee at the Centre Azm for Research in Biotechnology (Lebanese University, CE-EDST-10–2019) and the medical administration at Rahma Hospital for Rehabilitation. A single, comprehensive original approval document covered the entire study period, verifying that formal ethical oversight was established well before the trial’s practical inception and maintained throughout. The flow of all participants through the screening, enrollment, randomization, and follow-up phases is illustrated in Fig 1. CONSORT flow diagram displaying the progress of all participants through the trial, including enrollment, intervention allocation, follow-up, and data analysis. Analysis was performed on an intention-to-treat basis with no participants lost to follow-up. Participants were screened by a specialized physician and excluded if they had major psychiatric diagnoses, cognitive impairments limiting instruction following, contraindications to tDCS, or were using medications known to inhibit tDCS effects (e.g., anti-epileptics, dopaminergics). Blinding Due to the distinct and active nature of the therapeutic protocols (e.g., active motor imagery and peripheral sensory stimulation versus conventional physical therapy), it was not feasible to blind the participants or the treating therapists to the group allocation. Therefore, the study was designed as a single-blind trial with strictly blinded outcome assessment. The Outcome Assessors—specialized physical therapists responsible for performing all baseline and post-intervention evaluations (ISNCSCI/ASIA and AMA)—were completely blinded to the participants’ group allocations and were not involved in delivering any treatment interventions. To maintain the integrity of this blinding, participants were explicitly instructed not to discuss their assigned treatment protocols, daily activities, or the use of neurostimulation equipment with the assessors. Furthermore, the data analysts performed all statistical analyses on coded datasets without knowledge of the specific intervention received by each group. Randomization and allocation concealment The random allocation sequence was generated using a web-based computer random number generator (www.random.org) to ensure a truly random and unbiased assignment. The generation process was performed by an independent investigator who was not involved in participant recruitment, treatment, or clinical assessment. Participants were allocated in a 1:2:2 ratio to the Reference (n = 10), NEUROM (n = 20), or NEUROM+tDCS (n = 20) groups, respectively. Allocation concealment was maintained by revealing the group assignment to the treating therapists only after the participant had completed baseline assessments and signed the informed consent. Experimental procedure Following baseline assessment (Day 1), participants were randomized into one of three distinct intervention arms: the Reference Group (standardized conventional care), the NEUROM Group (motor imagery combined with peripheral sensory stimulation), and the NEUROM+tDCS Group (cortical priming followed by the NEUROM protocol). To ensure strict reproducibility, treatment fidelity, and standardized application across all therapists, the complete step-by-step methodology for these interventions has been deposited in protocols.io. This includes the precise sequencing of the sensory-motor recruitment phases, as well as the evidence-based rationale and neurophysiological justification for the selected tDCS parameters (1.0 mA, bilateral anodal stimulation over M1). The full, open-access protocol is available at: https://dx.doi.org/10.17504/protocols.io.5qpvoe6bzl4o/v1. Reference Group (Control, n=10) (3 weeks). Reference Group (Control, n=10) (3 weeks). Participants in this group received a standardized conventional rehabilitation protocol that was implemented to account for spontaneous recovery and the influence of routine interaction. Each session comprised a structured regimen beginning with 20 minutes of both passive and active mobilization exercises aimed at maintaining joint flexibility and muscle activity. This was followed by 15 minutes of standing using a passive standing frame, providing postural support and weight-bearing stimulation without active effort from the patient. The session concluded with 10 minutes focused on sitting posture training to enhance trunk control and stability. Notably, participants in this protocol did not receive any electrical stimulation or specific motor imagery training, ensuring that any observed improvements could be attributed to the standardized rehabilitation activities alone. NEUROM Group (n=20) NEUROM Group (n=20) Participants in the NEUROM group (n = 20) underwent the Neuromotor Recruitment Method, a protocol designed to integrate central motor planning with peripheral sensory feedback through a structured three-phase approach. Phase 1: Motor Imagery Training (One week- 6 days) These daily sessions involve static stretching of the lower limbs, specifically the hamstrings and triceps muscles, for 15 minutes. Each stretching bout lasts for 2 minutes without rest. Following the stretching exercises, patients undergo motor imagery training, which consists of three different modalities described as follows: aAction observation: Patients watch a short video demonstrating repetitive plantar and dorsal flexion movements (Fig 2). The video lasts for 1 minute, with auditory feedback provided at a tempo of 20 beats per minute (bpm). Action observation: Patients watch a short video demonstrating repetitive plantar and dorsal flexion movements (Fig 2). The video lasts for 1 minute, with auditory feedback provided at a tempo of 20 beats per minute (bpm). bVisual imagery in the third-person perspective: Patients are instructed to vividly create a mental image of the observed video (dorsiflexion-plantar flexion) for one minute. This is done in the same position and in a darkened treatment room. The start and end of the imagined movement are guided by the same auditory cues of 20 bpm. Visual imagery in the third-person perspective: Patients are instructed to vividly create a mental image of the observed video (dorsiflexion-plantar flexion) for one minute. This is done in the same position and in a darkened treatment room. The start and end of the imagined movement are guided by the same auditory cues of 20 bpm. cKinesthetic imagery: The physical therapist guides the patient to imagine performing the same foot movement without physically executing it. Patients are instructed to close their eyes during this phase and focus on feeling the movement. Kinesthetic imagery: The physical therapist guides the patient to imagine performing the same foot movement without physically executing it. Patients are instructed to close their eyes during this phase and focus on feeling the movement. Screenshots from the video showed to participants in the AO phase. These three phases of motor imagery training are repeated in 20 trials with 2 sets per session. To minimize expectation effects, stimuli are presented in a pseudo-randomized order between phase 2 and 3 of the motor imagery training for each trial. Patients are instructed to maintain a forward gaze throughout the entire experiment. Verbal instructions are delivered binaurally through earphones using Presentation software (Neurobehavioral Systems® [18], version 25). All auditory materials and verbal instructions are recorded and processed using Audacity (version 3.0.3). The instructions are normalized to ensure equal sound levels. Phase 2: NEUROM (2 weeks – 4 sessions/week) In each session of this phase, the motor imagery (MI) training described in Phase 1 is reiterated at the outset and prior to commencing the NEUROM protocol. The MI training consists of the patients performing 2 sets of imagery, with 20 repetitions per set. Additionally, a global stretching of the muscles in the lower limbs is conducted to prepare for the introduction of the MI training in the NEUROM protocol. To begin the NEUROM protocol, the patient is given the following instructions while keeping their eyes closed: “while eyes closed, try to remember the movements that were just demonstrated and experienced during the MI training, try to visualize the movements and reestablish a connection with both feet.” During this imagery exercise, the therapist incorporates a series of superficial sensory stimuli, including tactile vibrations, as well as global and rapid stretching of the lower limbs. The trial concludes by prompting the patients to move their ankles in any direction, making use of their maximum strength. This process of sensory sensitization and motor recruitment is repeated approximately 10 times, with variations in limb position, while additionally employing sensitization and facilitation techniques such as limb abduction, hamstring stretching, and dorsi/plantar flexor stretching of the ankles. Phase 3: Functional Rehabilitation (Standing between parallel bars, waking with technical aids if possible). NEUROM + tDCS Group (n=20) NEUROM + tDCS Group (n=20) The NEUROM + tDCS group (n = 20) followed the same Neuromotor Recruitment Method protocol described previously, with the addition of transcranial direct current stimulation (tDCS) administered prior to the physical therapy exercises to prime the motor cortex. Bilateral anodal tDCS was delivered using a StarStim multi-focal device (Neuroelectrics), with saline-soaked sponge electrodes measuring 35 cm² placed over the primary motor cortex (M1) of each hemisphere at locations C3 and C4 according to the 10–20 EEG system. The stimulation involved a current of 1.0 mA applied for 15 minutes on each side, totaling 30 minutes of stimulation, with a 30-second ramp-up and ramp-down period. The cathode electrodes were positioned over the contralateral supraorbital area. After the tDCS session, participants rested for 15 minutes before immediately beginning the NEUROM protocol, thereby integrating cortical priming with the established motor imagery, sensory-motor recruitment, and functional application phases. Briefly, the tDCS parameters for the combined group were selected based on established neurophysiological evidence. A 1.0 mA intensity was chosen over higher doses to provide a stable increase in corticospinal excitability while avoiding unpredictable, calcium-dependent plasticity shifts—such as cathodal stimulation paradoxically shifting from inhibition to facilitation at higher intensities [19,20]. Furthermore, a bilateral anodal montage (35 cm² electrodes over C3 and C4) was utilized to address the bilateral motor deficits inherent to paraplegia, simultaneously priming the leg motor representations of both hemispheres prior to peripheral neuromotor recruitment [21]. Safety and adverse event monitoring Although tDCS is widely recognized as a safe, non-invasive neuromodulation technique with no reports of serious adverse effects at intensities of 1–2 mA [22], mild and transient side effects—such as headache, cutaneous sensation (itching/tingling), fatigue, and skin redness—have been documented in the literature [23,24]. To ensure participant safety, a rigorous monitoring protocol was implemented throughout the study. First, all participants underwent a comprehensive pre-screening by a neurologist to rule out contraindications (e.g., history of seizures, metal implants). Second, all stimulation sessions were directly supervised by a senior neurorehabilitation specialist to monitor for immediate adverse reactions. Third, a structured safety questionnaire was administered immediately before and after each tDCS session to quantify any emerging symptoms (e.g., headache, scalp irritation, nausea, or acute mood changes). A pre-defined “stopping rule” was established wherein any reported symptom severity of 5/10 would result in immediate cessation of the session and withdrawal from the study; however, no severe adverse events or study withdrawals related to safety occurred. Outcome measures The primary outcome measures for this trial were the objective neurological assessments of motor and sensory recovery, specifically the Lower Extremity Motor Score (LEMS) and the ISNCSCI Light Touch and Pin Prick scores. The secondary outcome measure was the subjective evaluation of volitional drive using the Assessment of Movement Attempt (AMA) Scale. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)/ ASIA Protocols The ISNCSCI provides the standardized method for neurological assessment after spinal cord injury, covering detailed sensory and motor scoring. Sensory evaluation tests 28 dermatomes bilaterally for light touch and pin prick on a 0–2 scale, summing to maximum scores of 112 each. Motor assessment focuses on key muscle groups with strength graded on the 0–5 Medical Research Council (MRC) scale. The guidelines also include classification into ASIA Impairment Scale (AIS) grades A through D based on sensory and motor completeness/incompleteness. This protocol is detailed in the official ISNCSCI booklet and foundational papers by the American Spinal Injury Association (ASIA) [25,26]. Lower Extremity Motor Score (LEMS) The LEMS is a reliable metric for quantifying motor function in the lower limbs after spinal cord injury. It assesses five key muscle groups per leg in line with neurological myotomes (L2-S1), graded on the MRC 6-point scale. The total possible score is 50, with higher scores indicating better motor recovery. LEMS correlates well with ambulatory capabilities and has been widely used in clinical trials and outcome prediction studies [27–29]. Assessment of Movement Attempt (AMA) Scale The AMA scale evaluates volitional motor drive by asking patients to attempt movement of a paralyzed limb, with self-reported ratings for intensity and frequency of movement attempts. This subjective measure complements objective neurological scores to assess the restoration of volitional control. Research using AMA or similar scales focuses on the neurophysiological evaluation of residual motor function and recovery patterns below the injury level [30] and related functional outcome research in SCI [31]. Sample Size Justification An a priori power analysis was conducted (G*Power version 3.1) to determine the necessary sample size for a one-way ANCOVA with three groups and one covariate. To detect a large effect size (f=0.45) based on previous neurostimulation literature, with a significance level (α) of 0.05 and a statistical power of 80%, a total minimum sample size of 48 participants was calculated. To account for potential dropouts or non-compliance, a total of 50 participants were recruited and randomized. Statistical analysis All statistical analyses were planned and performed according to the intention-to-treat (ITT) principle. There was no sample loss or dropouts, as all 50 randomized participants completed the study and were included in the final analysis. Statistical analyses were performed using Python statistical libraries (SciPy Stats 1.10; Statsmodels 0.14). The normality of data distribution was assessed using the Shapiro-Wilk test, and Levene’s test was used to verify the assumption of homogeneity of variances. Baseline demographic and clinical characteristics were compared across the three groups using One-Way Analysis of Variance (ANOVA) for continuous variables and the Kruskal-Wallis H test for ordinal variables to ensure randomization resulted in balanced groups. To rigorously evaluate the impact of the interventions on continuous primary outcomes (ASIA Lower Extremity Motor Scores and Light Touch Sensory Scores), a One-Way Analysis of Covariance (ANCOVA) was conducted. The post-intervention score was defined as the dependent variable, the Treatment Group (Reference, NEUROM, NEUROM+tDCS) as the fixed factor, and the baseline (pre-intervention) score as the covariate. For ordinal outcome measures (Assessment of Movement Attempt [AMA] Intensity and Frequency), non-parametric tests were employed. Within-group changes (Pre vs. Post) were analyzed using the Wilcoxon Signed-Rank Test. Between-group differences at the post-intervention time point were analyzed using the Kruskal-Wallis H Test. Where significant between-group differences were found, Dunn’s post-hoc tests were performed with Bonferroni adjustment to identify specific group differences. Data are presented as mean (SD) for normally distributed continuous variables and as median (25th–75th percentiles) for ordinal or non-normally distributed data, adhering to the journal’s formatting guidelines. All reported p-values are two-tailed, with statistical significance set at. Results Baseline characteristics and chronicity Demographic and clinical characteristics for all 50 randomized participants are detailed in Table 1. There were no statistically significant differences between the three groups regarding age (p=0.57), gender (p=0.92), neurological level of injury (p=0.96), or baseline ASIA Impairment Scale (AIS) grade (p=0.75). Crucially, the study population represented a highly chronic cohort, with a mean time since injury of 15.4 ± 3.16 months (Range: 9–22 months). This extended duration—well beyond the 12-month window where spontaneous neurological recovery typically plateaus—confirms that the functional improvements observed in this trial are attributable to the therapeutic interventions rather than natural history. Furthermore, the distribution of injury severity was balanced, with 30% of participants classified as AIS A (motor-complete) and 70% as AIS B/C (incomplete), ensuring that injury completeness did not confound the treatment effects. 10.1371/journal.pone.0352320.t001Table 1Baseline Demographic and Clinical Characteristics.CharacteristicReference (n = 10)NEUROM (n = 20)NEUROM+tDCS (n = 20)P-valueAge (years), Mean (SD)28.6 (8.0)29.8 (5.4)31.1 (6.1)0.57 {a}Time since Injury (months), Mean (SD)13.7 (2.5)16.1 (3.2)15.5 (3.2)0.14 {a}Gender (Male/Female), n8/216/415/50.92 {b}Neurological Level, n (%)0.96 {b} Thoracic (T1–T10)4 (40%)7 (35%)7 (35%)– Thoracolumbar (T11–L1)6 (60%)13 (65%)13 (65%)–ASIA Impairment Scale (AIS), n (%)0.75 {b} AIS A (Complete)3 (30%)5 (25%)7 (35%)– AIS B (Sensory Incomplete)7 (70%)14 (70%)11 (55%)– AIS C (Motor Incomplete)0 (0%)1 (5%)2 (10%)–Note: SD = Standard Deviation. {a} One-way ANOVA; {b} Chi-square test. Baseline Demographic and Clinical Characteristics. Note: SD = Standard Deviation. {a} One-way ANOVA; {b} Chi-square test. Motor Recovery (LEMS) The Reference group demonstrated a stable baseline with no significant motor recovery (mean pre-to-post change: 0.2 (0.6) points). To isolate the effect of the intervention, a one-way ANCOVA was conducted on post-intervention Lower Extremity Motor Scores (LEMS) with baseline scores as a covariate. The analysis revealed a highly significant main effect of the treatment group F(2, 46)=53.1, p<0.001, with a large effect size (partial ηp2=0.70). Post-hoc analysis of the estimated marginal means confirmed that the NEUROM+tDCS group achieved the superior outcome (mean pre-to-post increase: 18.8 (4.6) points). This was significantly higher than both the NEUROMgroup (mean increase: 14.3 (5.6) points;) and the Reference group p<0.001. These results indicate that while the NEUROM protocol alone improves motor function, the addition of tDCS provides a statistically significant additive benefit (Fig 3). Effects of NEUROM and tDCS interventions on Lower Extremity Motor Score (LEMS) recovery. Mean change in Lower Extremity Motor Score (LEMS) recovery. The NEUROM+tDCS group demonstrated a significantly greater additive improvement compared to both the NEUROM-only (* P < 0.05) and Reference ( P < 0.001) groups, indicating a specific benefit of tDCS on motor output. Note: Total analyzed sample size N = 50 (Reference: n = 10; NEUROM: n = 20; NEUROM+tDCS: n = 20). Bar charts display Mean + Standard Deviation (SD). * P < 0.05, P < 0.001. Sensory recovery (light touch and pin prick) Regarding sensory function, the ANCOVA indicated a significant main effect of group for both modalities, with large effect sizes observed for each. Light Touch: Both active groups demonstrated better improvements compared to the Reference group 0.3(0.5); ϝ(2, 46)=236.9, p<0.001); ηp2=0.91. The NEUROM group showed a mean change of 58.4 (9.6) points, and the NEUROM+tDCS group showed a mean change of 62.8 (10.3) points. Light Touch: Both active groups demonstrated better improvements compared to the Reference group 0.3(0.5); ϝ(2, 46)=236.9, p<0.001); ηp2=0.91. The NEUROM group showed a mean change of 58.4 (9.6) points, and the NEUROM+tDCS group showed a mean change of 62.8 (10.3) points. Pin Prick: Similarly, for pain sensation, significant group differences were found F(2, 46)=178.8, p<0.001; ηp2=0.89. The NEUROM group showed a mean change of 56.1 (10.8) points, while the NEUROM+tDCS group showed a mean change of 60.85 (10.6) points. Pin Prick: Similarly, for pain sensation, significant group differences were found F(2, 46)=178.8, p<0.001; ηp2=0.89. The NEUROM group showed a mean change of 56.1 (10.8) points, while the NEUROM+tDCS group showed a mean change of 60.85 (10.6) points. Crucially, for both Light Touch and Pin Prick, the difference between the NEUROM and NEUROM+tDCS groups was not statistically significant p>0.05. This consistent finding across both sensory modalities suggests that the peripheral recruitment component of the NEUROM protocol was the primary driver of sensory recovery, with tDCS providing no significant additional gain in this domain (Fig 4 and 5). Effects of NEUROM and tDCS interventions on Light Touch sensory recovery. Mean change in sensory recovery for Light Touch scores. Both active groups (NEUROM and NEUROM+tDCS) improved significantly compared to the Reference group ( P < 0.001) across the sensory modality, with no statistically significant difference observed between the two active intervention arms. Effects of NEUROM and tDCS interventions on Pin Prick sensory recovery. Mean change in sensory recovery for Pin Prick scores. Both active groups (NEUROM and NEUROM+tDCS) improved significantly compared to the Reference group (P < 0.001) across the sensory modality, with no statistically significant difference observed between the two active intervention arms. Volitional Drive (AMA) Intensity of Attempt A Kruskal-Wallis test showed significant differences in the subjective intensity of motor attempts between groups (H=39.89, p<0.001)). The NEUROM+tDCS group reported the highest intensity [Median: 5.2 (25th–75th percentiles: 5.0–5.5)], representing a “strong/vivid” feeling of movement. This was significantly higher than the Reference group [Median: 1.5 (1.5–2.0); p < 0.001] and the NEUROM group [Median: 3.8 (3.0–4.1); p < 0.001] (Fig 6). Subjective Assessment of Movement Attempt (AMA) Intensity scores. Evaluation of the Intensity of subjective movement attempts. The combined NEUROM+tDCS group reported significantly higher intensity of limb use compared to both the NEUROM and Reference groups ( P < 0.001), aligning with the objective motor gains. Frequency of Spontaneous Use: Similarly, the frequency of spontaneous limb use in daily life differed significantly across groups (p < 0.001). The combined group reported the highest frequency [Median: 5.0 (4.9–5.5)], significantly exceeding the NEUROM group [Median: 3.0 (2.0–3.1); p < 0.001] and the Reference group [Median: 1.8 (1.0−2.0);p<0.001] (Fig 7). Subjective Assessment of Movement Attempt (AMA) Frequency scores. Evaluation of the Frequency of subjective movement attempts. The combined NEUROM+tDCS group reported significantly higher frequency of limb use compared to both the NEUROM and Reference groups ( P < 0.001), aligning with the objective motor gains. Discussion The combined effect of central and peripheral activation Despite the limited capacity for spontaneous regeneration in the adult CNS, individuals with incomplete SCI often demonstrate substantial recovery. This recovery is likely due to the reorganization of spared neural circuits and synaptic plasticity [32]. Our findings confirm that significant functional recovery is achievable in chronic SCI through targeted reorganization. Neural plasticity after SCI, including synaptic remodeling, axonal sprouting, and circuit reorganization, is a major contributor to spontaneous and therapy-driven functional recovery. Recent reviews examine enhancing plasticity through spinal interneuron engagement and various therapeutic approaches targeting these mechanisms [33,34]. This study demonstrates a clear hierarchical benefit: while the NEUROM protocol alone outperformed conventional rehabilitation, the combination of NEUROM and tDCS produced better improvements. For motor function, the combination of NEUROM and tDCS produced better improvements, significantly outperforming both the Reference group and the NEUROM-only group. This confirms an additive effect where central modulation (tDCS) amplifies the benefits of peripheral training. Interestingly, for sensory function (Light Touch and Pin Prick), both active groups achieved massive gains compared to the Reference group, but the addition of tDCS did not yield a statistically significant advantage over NEUROM alone. This suggests that the intense peripheral stretching and sensory recruitment inherent to the NEUROM protocol may be sufficient to maximally drive sensory plasticity, potentially reaching a “ceiling effect” that tDCS over the motor cortex does not further enhance. Mechanism of recovery: Closing the sensorimotor loop The superior performance of the NEUROM + tDCS group supports the hypothesis of a bidirectional enhancement of plasticity. We propose that tDCS “primes” the primary motor cortex (M1), lowering the activation threshold for motor neurons [32,35]. Simultaneously, the NEUROM protocol provides intense bottom-up peripheral sensory input (via stretching and vibration) while engaging top-down motor planning (via imagery). By synchronizing the “intent to move” (facilitated by tDCS and imagery) with “sensory feedback” (provided by NEUROM), we probably facilitated Hebbian plasticity—strengthening the synaptic connections in spared interneuron networks [36]. This aligns with recent literature suggesting that combining central modulation with peripheral feedback is far more effective than either modality in isolation [37,16]. Restoration of volitional drive (AMA assessment) A critical behavioral and neural correlate of recovery is the patient’s ability to generate a “movement attempt.” Our analysis of the AMA scores showed that patients in the combined intervention group reported significantly higher intensity of movement attempts (Median 5.0 vs. 1.5 in the reference group), reflecting a robust restoration of volitional motor drive rather than merely a reduction in effort. This aligns with findings in recent literature where combining tDCS with motor imagery enhances the excitability of motor-related cortical areas, thus strengthening the neural signals associated with movement attempts [38]. The tDCS-induced increase in cortical excitability likely made the motor imagery tasks more vivid and helped patients experience a clearer, more direct neural connection to their paralyzed limbs. This neurophysiological facilitation has been reported to amplify the sense of agency and promote recovery of motor control in clinical populations (e.g., stroke and spinal cord injury patients) through enhanced motor relearning processes [39]. Importantly, this enhancement of volitional drive was not limited to clinical assessments but translated into everyday behavior. Patients in the combined group reported significantly higher frequency of spontaneous limb use, indicative of increased confidence and integration of regained motor control into daily activities. Such transfer of gains from structured rehabilitation to spontaneous functional use is crucial and has been documented in related studies evaluating the functional benefits of tDCS combined with mental imagery or robotic rehabilitation methods [40]. While the results of this study are promising, they must be interpreted within the context of several limitations. First, the intervention period was relatively short (3 weeks), and the sample sizes were modest with an uneven distribution; while the smaller reference group (n = 10) was designed primarily to rule out spontaneous recovery, this inequality remains a statistical limitation. Second, due to the active nature of the physical interventions, it was not possible to double-blind the participants or treating therapists, though outcome assessors remained strictly blinded. Finally, the current findings are based solely on a specific sample derived from our local population. Conclusion This trial suggests that combining central excitability (via tDCS) with intense peripheral neuromotor recruitment (the NEUROM protocol) may offer a clinically valuable strategy for enhancing sensorimotor recovery in chronic spinal cord injury. Rather than replacing compensatory rehabilitation, our data indicate that synchronizing central and peripheral interventions could serve as a beneficial adjunct to maximize functional gains. However, future randomized controlled trials with much larger sample sizes, conducted across diverse geographical areas, and including longitudinal follow-ups are essential to confirm the long-term effectiveness and clinical sustainability of the NEUROM+tDCS protocol. Supporting information CONSORT 2025 Checklist. The completed CONSORT institutional checklist detailing compliance with reporting standards for randomized controlled trials. (DOCX) Request for Ethical Opinion Document. The official documentation and ethical clearance application submitted to the institutional review framework, presented without institutional logos. (PDF) Detailed Research Protocol Document. The comprehensive study protocol outlining the specific methodologies, interventions, and safety monitoring plans for the clinical trial evaluating the NEUROM and tDCS interventions. (PDF) Abstract figure. (PNG) 15 Apr 2026 -->PONE-D-26-07973-->-->Synergistic Effect of tDCS and Neuromotor Recruitment on Functional Recovery in Chronic Paraplegia: A Randomized Controlled Trial-->-->PLOS One Dear Dr. Rifai Sarraj, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 30 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Mohammad Sidiq, PhD Physiotherapy, FAIMER Fellow Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript. 3. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study. As per the journal’s editorial policy, please include in the Methods section of your paper: a) your reasons for your delay in registering this study (after enrolment of participants started); b) confirmation that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered” 4, In the online submission form, you indicated that [All relevant data are within the manuscript and its Supporting Information files UPON REQUEST]. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 5.Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments (if provided): The article is an interesting and clinically relevant randomized controlled trial that presents the answer to a particular question in the field of neurorehabilitation. Although the topic is quite timely and the results can make a difference, there are some issues connected to clarity of the methodology, transparency of reporting, and following the journal rules. As it stands, the publication needs significant revision before it can be accepted to the standards of scientific rigor in various aspects, including consistency in the study design, statistical presentation, and availability of data. The response to such issues will enhance the validity and interpretability of findings and enhance the overall quality of the manuscript. Here are my comments apart from the reviewer observations as under 1. Registration and clarification of the study. The manuscript mentions the trial registration (NCT04790149), but it appears to be post hoc to the start of the study. The Method section must explain the delay (not just the cover letter) and confirm that there were no protocol changes after registration. 2. Blinding Inconsistency It is referred to as "single-blind" (Abstract) and "double-blind" (Methods). Inconsistency means that something went wrong here; please clarify who was blinded. 3. Data Availability Statement - non-simultaneous. The existing statement (available upon request) is against journal policy. Authors are required to save data in an open-source repository, or informative restrictions need to be explained. 4. Sample Size Justification Although it is stated that a priori power analysis was conducted, no specifications (effect size, power, or alpha) are provided. Kindly provide complete parameters and assumptions. 5. Control Group Description The intervention of the "reference group” is in need of a more detailed explanation. Discuss the reason this is normal care and whether or not intensity/dosage can be equated with intervention arms. 6. Statistical Reporting Issues P-values and other statistics are not fully worked out or formatted wrongly (e.g., an empty value in Results). Always report F-values, degrees of freedom, exact p-values, and sizes of effects. 7. Outcome Measures - Validity and Novelty. The AMA scale should have better validation or citation support, as it does not seem as standardized as ISNCSCI/LEMS. 8. Short Intervention Duration Chronic SCI has a fairly low intervention duration of 10 days/3 weeks. Clinical relevance should be better justified by the authors, and effects on sustainability should be discussed. 9. Mechanistic Claims Overstated The mentioning of the so-called Hebbian plasticity or the top-down and bottom-up mechanisms are both speculative statements. Be less conclusive or provide more supporting evidence. 10. Figures and Reporting Figures (graphical abstract, Figures 1-3) are mentioned but not wholly incorporated and discussed in the descriptive details. ensure that figures are of journal quality and are labeled. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Overview and general recommendation: Thank you for giving me the opportunity to review the manuscript entitled “Synergistic Effect of tDCS and Neuromotor Recruitment on Functional Recovery in Chronic Paraplegia: A Randomized Controlled Trial”. The findings of this study are expected to contribute meaningfully to the body of knowledge in the field and support the development of more effective treatment strategies for this population. The study is very well described, following CONSORT guidelines. The research proposal is relevant and aligns with the journal’s scope. Minor Comments The description of the Assessment of Movement Attempt (AMA) Scale is entirely in bold. Please correct this. Was the treatment protocol designed based on a previous study? If so, it would be helpful to clarify. Did the authors plan analyses according to the intention-to-treat principle? Was there no sample loss? Reviewer #2: The study addresses an important clinical question and contributes to neurorehabilitation literature. Study Design and Methodology The manuscript inconsistently reports the study as single-blind (Abstract) and double-blind (Methods), which creates confusion. Clarification is essential. The control group size (n=10) is considerably smaller than intervention groups (n=20 each), raising concerns about statistical power and group comparability. Although randomization is described, allocation concealment details remain insufficient, particularly regarding implementation and sequence security. No sample size calculation or power analysis details are clearly described in the manuscript body, which is a critical requirement for RCTs. The NEUROM protocol is described in detail; however: The standardization and reproducibility of sensory stimulation and therapist-dependent techniques are unclear. There is no mention of treatment fidelity assessment or inter-therapist reliability. The tDCS protocol lacks justification (e.g., rationale for 1 mA intensity, bilateral stimulation, duration). The selected outcomes (LEMS, sensory scores, AMA) are appropriate; The AMA scale lacks sufficient validation details and references for clinical applicability. No primary vs. secondary outcome distinction is explicitly stated. The significance level (alpha) is missing in the statistical section. Effect sizes and confidence intervals are not consistently reported. There is no mention of handling missing data, although authors claim no loss to follow-up. The use of multiple comparisons correction needs clearer justification and reporting. The authors claim a “synergistic effect”, but: The absence of a tDCS-only group limits the ability to conclude synergy definitively. The conclusion about “top-down vs. bottom-up mechanisms” is interesting but appears overstated and speculative given the data. Clinical significance (not just statistical significance) is insufficiently discussed. The Data Availability Statement is non-compliant with PLOS guidelines, as “available upon request” contradicts journal policy. Trial registration is provided; It is unclear whether the trial was prospectively registered. Abstract Overly interpretative (mechanistic conclusions should be toned down). Include confidence intervals and clarify primary outcomes. Introduction Provides good background, but:Some references are outdated. The research gap and novelty could be more explicitly stated. Methods Minor grammatical and formatting issues present. Clarify: Inclusion criteria (e.g., chronicity threshold inconsistencies: >3 months vs. mean 15 months). Intervention duration inconsistency (10 days vs. 3 weeks mentioned). Results Should include effect sizes (optional ) and CI. Figures (e.g., CONSORT diagram) are referenced but not fully presented in the text. Discussion Strength: Integrates neuroplasticity concepts well. Limitations: Needs more critical appraisal of limitations, especially: Small sample size Lack of blinding Short intervention duration Overinterpretation should be reduced. References Some recent (last 5 years) high-impact studies on tDCS and SCI should be added. Recommendations for Improvement Clarify study design (single vs. double blind) Provide detailed sample size calculation Improve data availability compliance Include effect sizes and confidence intervals Add a clear distinction between primary and secondary outcomes Tone down causal and mechanistic claims Expand discussion on clinical implications and limitations Major Revision Required The manuscript has strong potential but requires substantial revisions in methodology reporting, statistical transparency, and interpretation before it can meet PLOS ONE publication standards. Reviewer #3: This manuscript presents data analysis from a three-arm randomized clinical trial in 50 individuals with chronic paraplegia, comparing a reference rehabilitation group, a NEUROM group, and a combined NEUROM+tDCS group. The topic is of importance, and the study was registered as a RCT within clinicaltrials.gov (with a valid NCT number), and was approved by the respective IRB/Ethics Committee. While the study objectives sound interesting, is important, and on target, some shortcomings were observed in regards to abiding by the CONSORT guidelines for conducting and reporting results of high-quality randomized controlled trials. 1. Methods: Methods reporting need some work. An orderly manner is suggested, following CONSORT guidelines, without repeating information, such as Trial Design, Participant Eligibility Criteria and settings, Interventions, Outcomes, sample size/power considerations, Interim analysis and stopping rules, Randomization (details on random number generation, allocation concealment, implementation), Blinding issues, etc, should be mentioned. The authors are advised to create "separate subsections" for each of the possible topics (whichever necessary), and that way produce a very clear writeup. They are advised to write it carefully, following nice examples in the manuscript below: https://www.sciencedirect.com/science/article/pii/S0889540619300010 Specific comments: (a) For instance, the randomization and allocation concealment should be made very clear (they are NOT the same thing); the trial staff recruiting patients should NOT have the randomization list. Randomization should be prepared by the trial statistician, and he/she would not participate in the recruiting. (b) More details on the randomization is needed; I could find no such details, other than saying that random numbers were generated via a web-based random generator. Was it a block randomization? What block size? Why was block randomization not conducted, since, BR helps to achieve equal sample sizes in the 2 arms. (c) There seems to be design inconsistency! The abstract describes the study as single-blind, whereas the Methods section describes it as double-blind, and the randomization section later clarifies that it was effectively single-blind with blinded outcome assessment, since participants and therapists could not be blinded. This is confusing. (d) Sample size: There doesn't seem to be any formal sample size/power statement provided! This is a serious limitation, given that the authors are analyzing data generated from a clinical trial. On the overall, the sample size seems to be small, wrt. a 3-arm superiority trial, with a variety of endpoints. (e) Statistical Analysis writeup (e1) The statistical analysis framework is not fully developed. Although ANCOVA (for continuous outcomes), and nonparametric tests (for ordinal outcomes) were used, there were no confidence intervals reported for treatment effects, no estimated adjusted mean differences, etc. (e2) There seems to be errors in the reported ANCOVA degrees of freedom; for example, (2, 52) = 35.6, but with a total n = 50 subjects, it's not clear how 52 appears in (2, 52). (e3) The single primary endpoint was not clearly mentioned, although, multiple outcomes were mentioned. (e4) The study design as analyzed does not formally test synergy in the statistical interaction sense; hence, the claims of synergy should be reduced. (e5) How missing data was handled is not clear. (e6) The analysis was intention-to-treat, yet, the CONSORT flow diagram consists of words like "Excluded from Analysis (give reasons)". Not clear. 2. Results & Conclusions: (a) The authors should check that any statement of significance should be followed by a p-value in the entire Results section. Otherwise, the Results section look OK; it's pretty straightforward. (b) Conclusions should state that the current findings are ONLY based on the samples derived from the specific population, and should allude to future studies with much larger sample sizes and collected at other geographical areas to confirm the effectiveness of the NEUROM+tDCS group, over the other groups. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 6 May 2026 Date: April 22, 2026 To: Dr. Mohammad Sidiq, PhD Physiotherapy, FAIMER Fellow Academic Editor, PLOS ONE Re: Resubmission of Manuscript PONE-D-26-07973 Title: Synergistic Effect of tDCS and Neuromotor Recruitment on Functional Recovery in Chronic Paraplegia: A Randomized Controlled Trial Dear Dr. Sidiq and Reviewers, We sincerely thank the Academic Editor and the Reviewers for their thorough, constructive, and insightful feedback. We deeply appreciate the recognition of the clinical relevance of our work. Your rigorous review has significantly strengthened the transparency, methodology, and statistical reporting of this manuscript. We have carefully addressed all comments and revised the manuscript accordingly. Below is our point-by-point response to the issues raised. Responses to Journal Requirements and Academic Editor 1. Trial Registration Delay & Protocol Changes Editor Comment: The manuscript mentions the trial registration... but it appears to be post hoc to the start of the study. The Method section must explain the delay and confirm no protocol changes. Author Response: We have added a dedicated section titled "Trial Registration and Ethical Approval Timeline" to the Methods. We explicitly clarify that the administrative registration was delayed due to a strict, institution-mandated freeze on patient recruitment during the COVID-19 pandemic. We also included the required statement confirming that all ongoing and related trials are registered, and explicitly verified that no modifications were made to the study design after registration. 2. Blinding Inconsistency Editor Comment: It is referred to as "single-blind" (Abstract) and "double-blind" (Methods). Inconsistency means that something went wrong here; please clarify who was blinded. Author Response: We apologize for this confusing oversight. The study was a single-blind trial with strictly blinded outcome assessment. We have corrected the word "double-blind" in the Methods section. Furthermore, we have added a dedicated "Blinding" sub-heading in the Methods detailing that while it was impossible to blind participants or treating therapists due to the active nature of the physical interventions, all Outcome Assessors and Data Analysts were completely blinded to group allocation. 3. Data Availability Statement Editor Comment: The existing statement (available upon request) is against journal policy. Author Response: We acknowledge this policy. We will upload the raw, de-identified dataset as a Supporting Information file alongside this resubmission to ensure full compliance with PLOS ONE open-data guidelines. 4. Sample Size Justification Editor Comment: No specifications (effect size, power, or alpha) are provided for the a priori power analysis. Author Response: We have added a "Sample Size Justification" sub-heading at the beginning of the Statistical Analysis section. We detail the parameters used in G*Power 3.1: identifying a large effect size (f = 0.45), α = 0.05, and 80% power, which yielded a required minimum of 48 participants, justifying our randomized sample of 50. 5. Control Group Description & Protocol Standardization Editor Comment: The intervention of the "reference group” needs detailed explanation. Author Response: We have thoroughly expanded the description of the Reference Group under "Experimental Procedure." To further ensure total transparency, reproducibility, and standardization of the NEUROM and Reference protocols, we have deposited our complete, step-by-step clinical methodology on protocols.io and provided the direct DOI link within the manuscript text. 6. Statistical Reporting Issues Editor Comment: P-values and other statistics are not fully worked out or formatted wrongly. Author Response: We have reviewed and corrected all statistical reporting. We identified and fixed a typographical error in our ANCOVA degrees of freedom (corrected from 52 to 46, reflecting our N=50 sample size). 7. Mechanistic Claims Overstated Editor Comment: Mentioning Hebbian plasticity or top-down/bottom-up mechanisms are speculative statements. Be less conclusive. Author Response: We agree. We have carefully revised the Discussion and Conclusion sections to tone down these mechanistic claims. We now present these mechanisms as evidence-based proposals rather than definitive conclusions, and we have softened our concluding language to reflect that this protocol is a "beneficial adjunct" rather than a definitive cure. Responses to Reviewer #1 Comment 1.1: The description of the Assessment of Movement Attempt (AMA) Scale is entirely in bold. Please correct this. Author Response: This formatting error has been corrected. Comment 1.2: Was the treatment protocol designed based on a previous study? If so, it would be helpful to clarify. Author Response: We appreciate the opportunity to clarify the theoretical origins of our protocol. The complete treatment protocol is a synthesis of established clinical practices rather than a direct replication of a single previous study. Specifically, the NEUROM protocol was inspired by general, evidence-based procedures widely reported throughout the spinal cord injury (SCI) neurorehabilitation literature. Comment 1.3: Did the authors plan analyses according to the intention-to-treat principle? Was there no sample loss? Author Response: Yes. We have now explicitly added a statement at the beginning of the Statistical Analysis section confirming that all analyses were planned and performed according to the intention-to-treat (ITT) principle. We also confirmed in the text that there was zero sample loss, as all 50 randomized participants completed the trial and were included in the final analysis. Responses to Reviewer #2 Comment 2.1: Clarify primary vs. secondary outcomes. Also validation of AMA scale. Author Response: We have added an explicit clarifying sentence under the "Outcome Measures" heading, designating the LEMS and ISNCSCI sensory scores as the primary objective outcomes, and the AMA scale as the secondary subjective outcome. In addition, we don’t have validation of AMA scale. Tha’s why we put it in the secondary outcome. It describes only the subjective feelings of the participant about its ability to movement. Comment 2.2: The control group size (n=10) is considerably smaller than intervention groups (n=20 each), raising concerns. Limitations: Needs more critical appraisal... small sample size, lack of blinding, short intervention duration. Author Response: We acknowledge these valid concerns. Regarding the unequal group distribution, we designed the trial with a smaller reference group (n=10) because its primary methodological purpose was simply to rule out the possibility of spontaneous recovery in this highly chronic cohort, thereby isolating and confirming the specific effects of the active interventions. However, we fully recognize that this 1:2:2 allocation remains a statistical limitation. Accordingly, we have entirely rewritten the "Limitations and Conclusion" section to explicitly highlight this uneven group distribution, alongside the modest overall sample size, the short 3-week intervention duration, and the fact that the physical nature of the therapy prevented double-blinding.. Comment 2.3: tDCS protocol lacks justification (e.g., rationale for 1 mA intensity, bilateral stimulation, duration). Author Response: We greatly appreciate this point. To address this directly, we have added a concise, referenced neurophysiological rationale for the 1.0 mA intensity (avoiding the unpredictable calcium-dependent plasticity shifts seen at higher doses) and the bilateral montage to the Experimental Procedure section of the manuscript. The complete, step-by-step clinical methodology and extended justification are also formally housed in our protocols.io entry, which is now cited in the text.. Responses to Reviewer #3 Comment 3.1: There seems to be errors in the reported ANCOVA degrees of freedom; for example, (2, 52) = 35.6, but with a total n = 50 subjects... Author Response: We are very grateful to the reviewer for reporting this typographical error. The error degrees of freedom have been mathematically corrected throughout the Results section from 52 to 46 (reflecting N=50, 3 groups, and 1 covariate). Comment 3.2: The study design as analyzed does not formally test synergy in the statistical interaction sense; hence, the claims of synergy should be reduced. Author Response: We agree with this precise statistical observation. We have reviewed the manuscript to reduce claims of strict statistical "synergy," reframing the outcome as a "significant additive benefit" and toning down the mechanistic conclusions accordingly. Comment 3.3: Conclusions should state that the current findings are ONLY based on the samples derived from the specific population, and should allude to future studies with much larger sample sizes and collected at other geographical areas. Author Response: We completely agree with this precise statistical observation. Because our study design did not include a tDCS-only arm to formally test statistical interaction, we have systematically reviewed the manuscript to remove claims of strict statistical "synergy." Specifically, we have updated the Title of the manuscript to reflect an "Additive Benefit," and we have meticulously reframed the terminology throughout the Abstract, Introduction, Results, and Discussion sections to describe the outcomes as a "combined effect" or "significant additive benefit." We have also toned down the mechanistic conclusions accordingly to accurately reflect this additive nature without overstating the statistical model. Complete Minimal Dataset & Open Access Repository As requested, we have verified that the uploaded Supporting Information files (CSV format) constitute the complete minimal dataset required to replicate all statistical tests and figures in this manuscript. To further guarantee permanent, open-access availability, we have also deposited this dataset into a dedicated repository, which is now live and accessible via DOI: 10.5281/zenodo.19692431. Response regarding Data Availability: Thank you for the clarification. We would like to share our data exclusively through the external Zenodo repository, as recommended. Please update our Data Availability statement to reflect that the complete minimal dataset underlying this study is permanently hosted and publicly accessible via the following DOI: 10.5281/zenodo.19692431.. To prevent redundancy and streamline the publication process, I have removed the duplicate CSV files from the Supporting Information inventory in the submission portal. Sincerely, Professor Ahmad Rifai Sarraj Director, MOHAR Research Laboratory Faculty of Public Health, Lebanese University Submitted filename: Response to Reviewers.docx 9 Jun 2026 Additive Effect of tDCS and Neuromotor Recruitment on Functional Recovery in Chronic Paraplegia: A Randomized Controlled Trial PONE-D-26-07973R1 Dear Sarraj, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter, and your manuscript will be scheduled for publication. Kind regards, Mohammad Sidiq, PhD, Physiotherapy, FAIMER Fellow Academic Editor PLOS One Additional Editor Comments (optional): Dear authors, I'm pleased to share that the current revision satisfies the quality and rigor as per PLOS ONE standards, and I'm happy to accept this version based on the positive feedback from the reviewers too. Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #2: Yes Reviewer #3: (No Response) ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #2: Yes Reviewer #3: (No Response) ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #2: Yes Reviewer #3: (No Response) ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #2: Yes Reviewer #3: (No Response) ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #2: The manuscript can be considered for publication in its current form. Thankyou for giving me the opportunity. Reviewer #3: (No Response) ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #2: No Reviewer #3: No ********** PONE-D-26-07973R1 PLOS One Dear Dr. Rifai Sarraj, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Mohammad Sidiq Academic Editor PLOS One